Hyaluronidase

Generic Name
Hyaluronidase
Brand Names
Amphadase
Drug Type
Biotech
Chemical Formula
-
CAS Number
9001-54-1
Unique Ingredient Identifier
8KOG53Z5EM
Background

Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluro...

Indication

Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.

Associated Conditions
-
Associated Therapies
Parenteral rehydration therapy, Parenteral drug administration, Subcutaneous urography

Hyaluronidase Assisted Subcutaneous Infusion

Phase 3
Completed
Conditions
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Shanghai Bao Pharmaceuticals Co., Ltd.
Target Recruit Count
45
Registration Number
NCT06604546
Locations
🇨🇳

Suzhou Municipal Hospital, Su Zhou, Jiangsu, China

Hyaluronidase Via LADD Scleroderma-induced Microstomia

Early Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-08-16
Last Posted Date
2024-10-16
Lead Sponsor
University of Nebraska
Target Recruit Count
10
Registration Number
NCT05995626
Locations
🇺🇸

University of Nebraska Medical Center, Lauritzen Outpatient Center, Omaha, Nebraska, United States

🇺🇸

Nebraska Medicine, Dermatology Westroads, Omaha, Nebraska, United States

Effect of Adding Hyaluronidase to Bupivacaine in Transversus Abdominis Plane Block for Cesarean Section

Not Applicable
Recruiting
Conditions
Interventions
First Posted Date
2023-01-04
Last Posted Date
2023-07-27
Lead Sponsor
Benha University
Target Recruit Count
90
Registration Number
NCT05671172
Locations
🇪🇬

Samar Rafik Amin, Banhā, Qalubia, Egypt

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

First Posted Date
2022-08-11
Last Posted Date
2024-03-05
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
44
Registration Number
NCT05498220
Locations
🇺🇸

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

First Posted Date
2022-01-25
Last Posted Date
2023-08-15
Lead Sponsor
Epizyme, Inc.
Registration Number
NCT05205252
Locations
🇺🇸

Central Care Cancer Center, Bolivar, Missouri, United States

🇺🇸

California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States

🇺🇸

Astera Cancer Center, East Brunswick, New Jersey, United States

Effectiveness of Adding Hyaluronidase to Bupivacaine in Ultrasound Guided Supraclavicular Brachial Plexus Block

Phase 2
Conditions
Interventions
First Posted Date
2021-10-19
Last Posted Date
2021-10-27
Lead Sponsor
Sohag University
Target Recruit Count
40
Registration Number
NCT05083663
Locations
🇪🇬

Sohag University Hospital, Sohag, Egypt

Ultrasound Guided Erector Spinae Plane Block in Breast Surgery

First Posted Date
2018-09-06
Last Posted Date
2020-04-09
Lead Sponsor
Assiut University
Target Recruit Count
60
Registration Number
NCT03660020
Locations
🇪🇬

Assiut university, Assiut, Egypt

Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study

First Posted Date
2018-01-26
Last Posted Date
2018-04-27
Lead Sponsor
Cairo University
Target Recruit Count
64
Registration Number
NCT03411330
Locations
🇪🇬

Ahmed Abdalla Mohamed, Cairo, Egypt

Peripheral Modulation of Muscle Stiffness and Spasticity

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2017-10-11
Last Posted Date
2024-11-18
Lead Sponsor
Johns Hopkins University
Target Recruit Count
56
Registration Number
NCT03306615
Locations
🇺🇸

Johns Hopkins School of Medicine, Baltimore, Maryland, United States

Effect of Hyaluronidase on Intraocular Pressure

Not Applicable
Conditions
Interventions
First Posted Date
2017-08-30
Last Posted Date
2017-08-30
Lead Sponsor
Assiut University
Target Recruit Count
50
Registration Number
NCT03266406
© Copyright 2024. All Rights Reserved by MedPath